Boston Scientific Corp. (NYSE:BSX) is touting the U.S. release of its Ion drug-eluting stent system as the first step toward bolstering its leadership position in the DES market.
The Ion paclitaxel-eluting stent, which is built on Boston Scientific’s next-generation platinum-chromium Element platform, won FDA approval for commercial release in the U.S. The stent, already available in Europe under the Taxus Element label, brought in just under $90 million in sales last quarter.